ADHD Medication Benefits and Risks Need Monitoring

New findings show ADHD medication can help reduce learning gaps in children while requiring ongoing heart health checks.

Updated on Oct. 28, 2026 in Autism

Gouache-painted editorial illustration showing brass scales balancing a jar of capsules against a stone heart, representing medical benefit-risk trade-offs.
New research shows that ADHD medications for children provide significant academic gains but necessitate careful long-term cardiovascular health monitoring by physicians. AI Illustration. Upload story photo >

Live Poll

Do you feel confident in the long-term health safety of ADHD medications prescribed to children?

New observational research reveals that while ADHD medications like methylphenidate can reduce learning gaps in children, they also show potential cardiovascular impacts over long-term use. These findings offer families and clinicians a clearer picture of the benefit-risk balance when managing ADHD in children and adolescents.

Why it matters

Understanding the long-term trade-offs of ADHD treatment is essential as global prescription rates continue to rise. This data helps patients and physicians weigh the academic advantages of medication against known physiological changes that require ongoing clinical monitoring.

The ADDUCE study followed 1,410 children and adolescents over 24 months, observing a 12% reduction in learning gaps alongside modest increases in heart rate and blood pressure. Long-term cardiovascular risks and the full scale of neurological outcomes remain under active investigation.

The players

European College of Neuropsychopharmacology

An independent scientific association that promotes research into the treatment of disorders of the brain.

The details

Methylphenidate functions by inhibiting the reuptake of dopamine and norepinephrine, which helps regulate focus and impulse control in the brain. Over the 24-month study period, children taking the medication experienced a rise in systolic blood pressure from 108 mm Hg to 113 mm Hg and an increase in heart rate from 80 beats/min to 83 beats/min. These physiological shifts are being evaluated alongside academic outcomes, where medication effectively closed learning gaps by approximately 12% compared to peers without ADHD.

Timeline

  1. 2015-2019 saw a nearly 10% annual increase in ADHD medication use across 64 countries.

  2. October 28, 2026, marked the presentation of these findings at the 39th Congress of the European College of Neuropsychopharmacology.

Health Landscape

The ADDUCE study provides critical long-term data that advances our understanding of ADHD treatment safety, mirroring the evolution of pediatric pharmacological monitoring. This research updates the known profile of common ADHD treatments by quantifying previously limited long-term data on cardiovascular and academic outcomes.

If you or your child take medication for ADHD, discuss the importance of routine heart rate and blood pressure monitoring with your physician. These findings reinforce that medication is one part of a comprehensive strategy and may not fully close learning gaps on its own.

The takeaway

While ADHD medications offer clear academic benefits, they also require careful long-term cardiovascular tracking. Prioritize regular checkups to monitor vitals and discuss with your doctor whether additional academic supports are needed to help address remaining learning gaps.

Further reading

For more information on managing neurodevelopmental support, visit Autism.

Source note: This article includes information reported by Medscape.

Live Poll

Do you feel confident in the long-term health safety of ADHD medications prescribed to children?